Search Result
Results for "
monoamine oxidase B (MAO-B)
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W001601
-
|
iGluR
|
Neurological Disease
|
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .
|
-
-
- HY-160002
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC50 values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .
|
-
-
- HY-147362
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.95 μM and a Ki of 0.55 μM against human MAO-B.
|
-
-
- HY-W001601R
-
|
iGluR
|
Neurological Disease
|
Budipine (Standard) is the analytical standard of Budipine. This product is intended for research and analytical applications. Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .
|
-
-
- HY-117502
-
|
Monoamine Oxidase
|
Others
|
SL-25.1188 is a potent monoamine oxidase B (MAO-B) inhibitor with Ki values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .
|
-
-
- HY-114915
-
-
-
- HY-146150
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity .
|
-
-
- HY-146149
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity .
|
-
-
- HY-151210
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC50 value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research .
|
-
-
- HY-151208
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC50 of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease .
|
-
-
- HY-143244
-
|
Monoamine Oxidase
|
Neurological Disease
|
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC50 of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .
|
-
-
- HY-143245
-
|
Monoamine Oxidase
|
Neurological Disease
|
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .
|
-
-
- HY-144824
-
|
Cytochrome P450
Monoamine Oxidase
|
Neurological Disease
Cancer
|
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC50s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .
|
-
-
- HY-W792513
-
|
Monoamine Oxidase
|
Neurological Disease
|
WAY-620147 (compound 6) is an N-(2-morpholinoethyl)nicotinamide derivative that inhibits monoamine oxidase (Monoamine Oxidase). WAY-620147 inhibits MAO-A and MAO-B with IC50s of 26 μM and 55 μM, respectively .
|
-
-
- HY-N9540
-
|
Monoamine Oxidase
|
Neurological Disease
|
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC50=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .
|
-
-
- HY-163380
-
|
Carbonic Anhydrase
|
Neurological Disease
|
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .
|
-
-
- HY-146347
-
|
Monoamine Oxidase
Amyloid-β
|
Neurological Disease
|
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC50 of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .
|
-
-
- HY-116097
-
|
Monoamine Oxidase
|
Neurological Disease
|
PSB-1491 is a selective and competitive monoamine oxidase B (MAO-B) inhibitor with an IC50 of 0.386 nM for hMAO-B. PSB-1491 shows >25000-fold selective versus MAO-A .
|
-
-
- HY-161328
-
|
Monoamine Oxidase
α-synuclein
Tau Protein
|
Neurological Disease
|
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC50 value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .
|
-
-
- HY-162061
-
|
Monoamine Oxidase
|
Neurological Disease
|
ChEs/MAOs-IN-1 (Compound 4i) is a dual inhibitor of cholinesterases (ChEs) and monoamine oxidases (MAOs).ChEs/MAOs-IN-1 has IC50 values of 0.048 μM, 0.89 μM, 3.58 μM, and 0.095 μM for AChE, BChE, MAO-B and MAO-B respectively. ChEs/MAOs-IN-1 can be used in the study of neurodegenerative diseases .
|
-
-
- HY-U00015
-
-
-
- HY-162303
-
|
Monoamine Oxidase
|
Neurological Disease
|
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .
|
-
-
- HY-U00343
-
-
-
- HY-157934
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC50 values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD) .
|
-
-
- HY-157981
-
|
Cholinesterase (ChE)
Monoamine Oxidase
|
Neurological Disease
|
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC50s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC50s of 353 nM and 716 nM, respectively .
|
-
-
- HY-163322
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-A inhibitor 2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC50 of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research .
|
-
-
- HY-146314
-
|
Monoamine Oxidase
Amyloid-β
|
Neurological Disease
|
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC50 of 0.18 μM. MAO-B-IN-9 prevents Aβ1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-151094
-
|
Monoamine Oxidase
|
Neurological Disease
|
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .
|
-
-
- HY-158092
-
|
Cholinesterase (ChE)
Monoamine Oxidase
|
Neurological Disease
|
ChEs/MAOs-IN-2 (compound a11) is a cholinesterases and monoamine oxidases inhibitor with IC50 value of 0.10, 0.20, 0.30, 0.40 µM for MAO-A, MAO-B, AChE, and BChE, respectively. ChEs/MAOs-IN-2 has the potential for the research of Alzheimer's disease .
|
-
-
- HY-B1558A
-
MCI-2016
|
Monoamine Oxidase
|
Neurological Disease
|
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease .
|
-
-
- HY-N7204
-
|
Monoamine Oxidase
Dopamine β-hydroxylase
|
Neurological Disease
|
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC50 of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase) activity. 4-Hydroxyderricin has antidepressant activity .
|
-
-
- HY-D0004
-
Azure B chloride
|
Monoamine Oxidase
|
Neurological Disease
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
-
-
- HY-14201
-
Ro 19-6327
|
Monoamine Oxidase
|
Neurological Disease
|
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .
|
-
-
- HY-14202
-
Ro 19-6327 hydrochloride
|
Monoamine Oxidase
|
Neurological Disease
|
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .
|
-
-
- HY-A0091
-
|
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-A0091A
-
|
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-103164
-
|
Adenosine Receptor
Monoamine Oxidase
|
Neurological Disease
|
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits monoamine oxidase B (MAO-B) with a Ki value of 70 nM by a pathway that is independent of its actions on the A2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research .
|
-
-
- HY-N1638
-
|
Monoamine Oxidase
|
Neurological Disease
|
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of MAO-B activity with the IC50 and Ki values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS .
|
-
-
- HY-19333
-
OG-L002
1 Publications Verification
|
Histone Demethylase
Monoamine Oxidase
HSV
|
Infection
|
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes .
|
-
-
- HY-N1636
-
|
Monoamine Oxidase
|
Neurological Disease
|
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective MAO-B (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC50 of 12.1 μM .
|
-
-
- HY-120419
-
|
Monoamine Oxidase
|
Neurological Disease
|
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-A0091AR
-
|
|
Cardiovascular Disease
Cancer
|
Pargyline (Standard) is the analytical standard of Pargyline. This product is intended for research and analytical applications. Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-101169
-
|
Monoamine Oxidase
|
Neurological Disease
|
Tetrindole mesylate is a selective inhibitor of monoamine oxidase A (MAO A). Tetrindole mesylate inhibits rat brain mitochondrial MAO A in a competitive manner with a Ki value of 0.4 μM and inhibits MAO B with a Ki of 110 μM. Tetrindole mesylate has antidepressant activity .
|
-
-
- HY-70057
-
FCE 26743; EMD 1195686
|
Monoamine Oxidase
|
Neurological Disease
|
Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .
|
-
-
- HY-W008566
-
Norharman; β-Carboline
|
Monoamine Oxidase
Endogenous Metabolite
|
Infection
Neurological Disease
Cancer
|
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC50 values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings .
|
-
-
- HY-10399
-
TV-3326
|
Monoamine Oxidase
Cholinesterase (ChE)
|
Neurological Disease
|
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-10399A
-
TV-3326 hydrochloride
|
Monoamine Oxidase
Cholinesterase (ChE)
|
Neurological Disease
|
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-13779A
-
|
Monoamine Oxidase
Dopamine Transporter
|
Neurological Disease
|
J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD) .
|
-
-
- HY-151562
-
|
Cholinesterase (ChE)
Monoamine Oxidase
|
Neurological Disease
|
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC50s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ1 and σ2 receptors with Ki values of 42.8 nM (human σ1 receptor) and 191 nM (rat σ2 receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .
|
-
-
- HY-70057A
-
FCE 26743 mesylate; EMD 1195686 mesylate
|
Monoamine Oxidase
|
Cardiovascular Disease
Neurological Disease
|
Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 nM) . Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al .
|
-
- HY-10400
-
TV-3326 hemitartrate
|
Monoamine Oxidase
Cholinesterase (ChE)
|
Neurological Disease
|
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-70057S1
-
FCE 26743-d4-1; EMD 1195686-d4-1
|
Isotope-Labeled Compounds
Monoamine Oxidase
|
Neurological Disease
|
Safinamide-d4-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].
|
-
- HY-70057R
-
|
|
Neurological Disease
|
Safinamide (Standard) is the analytical standard of Safinamide. This product is intended for research and analytical applications. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .
|
-
- HY-17447A
-
SKF 385 hydrochloride
|
Monoamine Oxidase
|
Neurological Disease
|
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .
|
-
- HY-14605
-
(R)-AGN1135 mesylate; TVP1012 mesylate
|
Monoamine Oxidase
Autophagy
Apoptosis
|
Neurological Disease
|
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline (mesylate) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14605A
-
(R)-AGN1135; TVP1012
|
Monoamine Oxidase
|
Neurological Disease
|
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14205
-
|
Monoamine Oxidase
|
Neurological Disease
|
NW-1772 (methanesulfonate) (22b) is a potent and selective monoamine oxidase (MAO) B inhibitor. NW-1772 (methanesulfonate) is the equivalent of HY-111156 NW-1772. NW-1772 has some advantages, such as rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. NW-1772 can be used for the research of neurodegenerative diseases .
|
-
- HY-14605S
-
(R)-AGN1135-13C3 mesylate; TVP1012-13C3 mesylate
|
Isotope-Labeled Compounds
|
Others
|
Rasagiline- 13C3 ((R)-AGN1135- 13C3; TVP1012- 13C3) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively .
|
-
- HY-13779
-
|
Monoamine Oxidase
Dopamine Transporter
|
Neurological Disease
|
(E/Z)-J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. (E/Z)-J147 can readily pass the blood brain barrier (BBB). (E/Z)-J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC50 values of 1.88 μM and 0.649 μM, respectively. (E/Z)-J147 has potential for the treatment of Alzheimer’s disease (AD) .
|
-
- HY-14605AR
-
|
Monoamine Oxidase
|
Neurological Disease
|
Rasagiline (Standard) is the analytical standard of Rasagiline. This product is intended for research and analytical applications. Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14605R
-
|
Monoamine Oxidase
Autophagy
Apoptosis
|
Neurological Disease
|
Rasagiline (mesylate) (Standard) is the analytical standard of Rasagiline (mesylate). This product is intended for research and analytical applications. Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline (mesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-17447AS
-
(1S,2R)-SKF 385-d5 hydrochloride
|
Monoamine Oxidase
|
Neurological Disease
|
(1S,2R)-Tranylcypromine-d5 (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D0004
-
Azure B chloride
|
Dyes
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14605S
-
|
Rasagiline- 13C3 ((R)-AGN1135- 13C3; TVP1012- 13C3) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively .
|
-
-
- HY-70057S1
-
|
Safinamide-d4-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].
|
-
-
- HY-17447AS
-
|
(1S,2R)-Tranylcypromine-d5 (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].
|
-
Cat. No. |
Compare |
Product Name |
Application |
Reactivity |
Compare Products
|
Products |
|
Cat. No. |
|
Host |
|
Reactivity |
|
Application |
|
Dilution Ratio |
|
Molecular Weight |
|
Conjugation |
|
Clonality |
|
Immunogen |
|
Appearance |
|
Isotype |
|
Gene ID |
|
SwissProt ID |
|
Purity |
|
Formulation |
|
Free Sample |
Yes
No
|
Size |
* This product has been "discontinued".
Optimized version of product available:
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-146314
-
|
|
Alkynes
|
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC50 of 0.18 μM. MAO-B-IN-9 prevents Aβ1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-A0091
-
|
|
Alkynes
|
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-A0091A
-
|
|
Alkynes
|
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-120419
-
|
|
Alkynes
|
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-10399
-
TV-3326
|
|
Alkynes
|
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-10399A
-
TV-3326 hydrochloride
|
|
Alkynes
|
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-10400
-
TV-3326 hemitartrate
|
|
Alkynes
|
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14605
-
(R)-AGN1135 mesylate; TVP1012 mesylate
|
|
Alkynes
|
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline (mesylate) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14605A
-
(R)-AGN1135; TVP1012
|
|
Alkynes
|
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively . Rasagiline is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: